

RFP単独耐性結核患者のリスクファクターは他の抗結核薬と同様、結核の治療歴の有無、服薬コンプライアンスの低下や不適切な治療による獲得耐性、HIV複合感染患者におけるINH、エタンプトール(EB)の吸収阻害(malabsorption)から生じるRFP耐性化¹⁾などが挙げられる。今回の対象はすべてHIV検査陰性であり、1名の既治療患者(No.441)以外は過去に結核症や結核以外の感染症でRFPを用いた化学療法を施された形跡はなかった。既治療患者No.441の初回治療時の感受性は不明だったが標準治療が施されており、同じく既治療のNo.21は初回治療時に既にRFP単独耐性であり、仮にRFP耐性化した株に感染したと考えるならば、これらの菌は伝播力が高い株であると思われる。同じVNTRパターンをもつグループAの2患者は、大阪府南部の隣接した市町村に居住していたが菌の分離時期は1年以上離れ、直接の接触歴も認められなかったため、実際同一菌株かどうかははっきりしない。しかし、結核菌が長期的に休眠と再燃を繰り返しながら広範囲に拡散し伝播する病原体であることから、地域で同一のRFP単独耐性結核菌が蔓延している可能性は拭いきれない。グループBの菌株も約4年間に散発しており、グループAと同様に同一クローン株である可能性が示唆され、地域内で感染拡大している危険性は無視できない。また、今回クラスターを形成しなかった菌株No.207と2名の既治療MDR-TB患者由来株は同じVNTRパターンを有していたが、両者に接触歴がないことからNo.207の多剤耐性誘導の可能性が示唆された。したがって、RFP単独耐性を含む耐性結核患者が関与する感染事例が発生した際には、接触者検診対象者に対する潜在性結核治療の徹底が求められる。

結核治療において、過去の結核治療歴や薬剤耐性を有する患者との接触の可能性、その地域での薬剤耐性状況等の情報を把握し薬剤耐性を有している可能性を常に考慮することは自明である。本研究から、上記の項目に加えて、耐性結核菌の分子生物学的特徴の把握と分子疫学解析の継続的な展開の重要性が示唆された。

文 献

- 1) 厚生労働省:「結核の統計 2010年版」. 結核予防会, 2010.
- 2) Tuberculosis Research Committee (Ryoken): Drug-resistant

- Mycobacterium tuberculosis* in Japan: a nationwide survey, 2002. *Int J Tuberc Lung Dis.* 2007; 11: 1129-1135.
- 3) World Health Organization: Global tuberculosis control 2010. World Health Organization, Geneva, 2010.
 - 4) Chang KC, Leung CC, Yew WW, et al.: Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. *Am J Respir Crit Care Med.* 2006; 174: 1153-1158.
 - 5) Kim BJ, Lee SH, Lyu MA, et al.: Identification of *Mycobacterial* Species by Comparative Sequence Analysis of the RNA Polymerase Gene (*rpoB*). *J Clin Microbiol.* 1999; 37: 1714-1720.
 - 6) Supply P, Allix C, Lesjean S, et al.: Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of *Mycobacterium tuberculosis*. *J Clin Microbiol.* 2006; 44: 4498-4510.
 - 7) 前田伸司, 村瀬良朗, 御手洗聡, 他: 国内結核菌型別のための迅速・簡便な反復配列多型(VNTR)分析システム—JATA(12)-VNTR分析法の実際. *結核.* 2008; 83: 673-678.
 - 8) Iwamoto T, Yoshida S, Suzuki K, et al.: Hypervariable loci that enhance the discriminatory ability of newly proposed 15-loci and 24-loci variable-number tandem repeat typing method on *Mycobacterium tuberculosis* strains predominated by the Beijing family. *FEMS Microbiol Lett.* 2007; 270: 67-74.
 - 9) Musser JM: Antimicrobial agent resistance in mycobacteria: molecular genetic insights. *Clin Microbiol Rev.* 1995; 8: 496-514.
 - 10) Hirano K, Abe C, Takahashi M: Mutations of *rpoB* gene of rifampin-resistant *Mycobacterium tuberculosis* strains isolated mostly in Asian countries and their rapid detection by line probe assay. *J Clin Microbiol.* 1999; 37: 2663-2666.
 - 11) Mulenga C, Chonde A, Bwalya IC, et al.: Low occurrence of tuberculosis drug resistance among pulmonary tuberculosis patients from an urban setting, with a long-running DOTS program in Zambia. *Tuberculosis Research and Treatment.* 2010; 2010: 1-6.
 - 12) Khuê PM, Truffot-Pernot C, Texier-Maugein J, et al.: A 10-year prospective surveillance of *Mycobacterium tuberculosis* drug resistance in France 1995-2004. *Eur Respir J.* 2007; 30: 937-944.
 - 13) The World Health Organization: WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world, Report No.4. 2008; WHO/HTM/TB/2008.394: Annex 1.

Short Report

MOLECULAR EPIDEMIOLOGY OF RIFAMPICIN MONO-RESISTANT
MYCOBACTERIUM TUBERCULOSIS

¹Shiomi YOSHIDA, ¹Kazunari TSUYUGUCHI, ²Katsuhiro SUZUKI, ³Motohisa TOMITA,
¹Masaji OKADA, ²Seiji HAYASHI, and ⁴Tomotada IWAMOTO

Abstract [Purpose] We aimed to investigate the prevalence and possible transmission routes of rifampicin (RFP) mono-resistant *Mycobacterium tuberculosis* strains.

[Methods] Drug susceptibility testing was used to identify 15 RFP-resistant strains out of 4,633 *M.tuberculosis* isolates. Sequencing of the *rpoB* gene and VNTR analysis were performed to further confirm the genetic classification.

[Results] Resistance-conferring mutations in the RFP resistance-determining region (RRDR) of the *rpoB* gene were found in 14 of the 15 strains with phenotypic RFP mono-resistance. VNTR analysis revealed 2 clusters of 5 identical strains each.

[Conclusions] Although the community prevalence of RFP mono-resistant *M.tuberculosis* is low, the results of VNTR analysis suggested that rather than being recently transmitted,

these strains may have been widely transmitted as latent infections in the population.

Key words : *Mycobacterium tuberculosis*, Rifampicin, *rpoB* gene, Drug susceptibility testing, VNTR

¹Clinical Research Center, ²Department of Respiratory Medicine, ³Department of Clinical Laboratory, National Hospital Organization Kinki-chuo Chest Medical Center, ⁴Kobe Institute of Health

Correspondence to: Shiomi Yoshida, Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka 591-8555 Japan. (E-mail: dustin@kch.hosp.go.jp)

Clinical Study

Frequent Detection of Anti-Tubercular-Glycolipid-IgG and -IgA Antibodies in Healthcare Workers with Latent Tuberculosis Infection in the Philippines.

Umme Ruman Siddiqi,¹ Prisca Susan A. Leano,² Haorile Chagan-Yasutan,¹ Beata Shiratori,¹ Hiroki Saitoh,¹ Yugo Ashino,¹ Yasuhiko Suzuki,³ Toshio Hattori,¹ and Elizabeth Freda O. Telan²

¹ Division of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan

² STD AIDS Cooperative Central Laboratory, San Lazaro Hospital, Manila, Philippines

³ Department of Global Epidemiology, Research Centre for Zoonosis Control, Hokkaido University, Sapporo, Japan

Correspondence should be addressed to Toshio Hattori, hatori286@yahoo.co.jp

Received 1 August 2011; Revised 12 December 2011; Accepted 26 December 2011

Academic Editor: Katalin Andrea Wilkinson

Copyright © 2012 Umme Ruman Siddiqi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anti-tubercular-glycolipid-IgG (TBGL-IgG) and -IgA (TBGL-IgA) antibodies, and the QuantiFERON-TB Gold test (QFT) were compared in healthcare workers (HCWs, $n = 31$) and asymptomatic human immunodeficiency virus-carriers (HIV-AC, $n = 56$) in Manila. In HCWs, 48%, 51%, and 19% were positive in QFT, TBGL-IgG, and -IgA, respectively. The TBGL-IgG positivity was significantly higher ($P = 0.02$) in QFT-positive than QFT-negative HCWs. Both TBGL-IgG- and -IgA-positive cases were only found in QFT-positive HCWs (27%). The plasma IFN- γ levels positively correlated with TBGL-IgA titers ($r = 0.74$, $P = 0.005$), but not TBGL-IgG titers in this group, indicating that mucosal immunity is involved in LTBI in immunocompetent individuals. The QFT positivity in HIV-AC was 31% in those with CD4+ cell counts $>350/\mu\text{L}$ and 12.5% in low CD4 group ($<350/\mu\text{L}$). 59% and 29% were positive for TBGL-IgG and -IgA, respectively, in HIV-AC, but no association was found between QFT and TBGL assays. TBGL-IgG-positive rates in QFT-positive and QFT-negative HIV-AC were 61% and 58%, and those of TBGL-IgA were 23% and 30%, respectively. The titers of TBGL-IgA were associated with serum IgA ($P = 0.02$) in HIV-AC. Elevations of TBGL-IgG and -IgA were related to latent tuberculosis infection in HCWs, but careful interpretation is necessary in HIV-AC.

1. Introduction

Although the incidence of tuberculosis has been falling since 2002, there were still 8.8 million incident cases of TB, 1.1 million deaths from TB, and an additional 0.35 million deaths from HIV-associated TB in 2010 [1]. The high rate of latent TB infection (LTBI) is one of the factors that make it difficult to achieve global control and eliminate TB [2]. The recent introduction of the immune-based interferon- γ release assay (IGRA) made a great impact on facilitating the diagnosis of LTBI [3] and clarified the high rate of infection in TB-high-risk populations including healthcare workers (HCWs) [4]. Attempts to detect LTBI in HIV-infected individuals were also facilitated by the development

of IGRA, although their higher rates of pseudonegative IGRA response due to low CD4+ T cell counts and diminished Th1 immunity cannot be ignored [5]. Trehalose 6,6-dimycolate (TDM), which constitutes a major part of the mycobacterial cell wall, was identified as the most immunogenic glycolipid and is produced predominantly by virulent MTB as well as by atypical mycobacteria [6]. Tubercular-glycolipid antigen (TBGL) consists of TDM purified from virulent mycobacterial strain H37Rv [7, 19]. The immunoglobulin-G to tubercular-glycolipid antigen (TBGL-IgG) has been proposed to be a useful marker for the serodiagnosis of active pulmonary tuberculosis (PTB) in Japan [7]. However, frequent elevated titers (17%) were also found in healthy elderly control people (age >40 years) in the same study,

and the possibility of LTBI was suggested by Maekura and colleagues [7]. Although IgA antibody to TBGL antigen (TBGL-IgA) was not evaluated earlier as a biomarker, strong association was revealed between the TBGL-IgG and -IgA titers in PTB cases [8]. Frequent positivity for TBGL-IgG (46%) and -IgA (36%) in healthy adults was also observed in our very recent study in Thailand, a TB-endemic country [9]. The TBGL-IgG-positive responses were not related to BCG vaccination [10]. Since both cellular-mediated and humoral immunity are necessary for an effective immune response against MTB, we aimed to clarify the relationship between the TBGL-IgG and -IgA responses with QuantiFERON-TB Gold In-Tube (QFT) assay system, in healthcare workers (HCWs) in a hospital of the Philippines.

Infection of human immunodeficiency virus (HIV) has substantially boosted the occurrence of tuberculosis (TB) disease worldwide [1]. The devastating association between HIV and TB is responsible for one of four TB-related deaths [11]. The East-Asian countries are predominantly TB endemic [1]. Similarly to Sub-Saharan Africa, the rapid, progressive increase of HIV infections in East-Asian countries may further accelerate TB infection in HIV/AIDS patients [12]. To clarify how HIV infection may alter immune responses in LTBI, newly diagnosed, asymptomatic, non-TB HIV-infected individuals were studied.

To understand the health condition of the individuals, we measured two TB-related biomarkers. Leptin, a cytokine-like hormone produced by bronchial epithelial cells and type II pneumocytes in addition to adipose tissue, exhibits a Th1-bias immune response [13]. Osteopontin (OPN) is a member of extracellular matrix proteins that is synthesized within the immune system by activated T cells, NK cells, dendritic cells, and macrophages. Involvement of OPN in Th1 immune responses has been reported [14]. OPN deficiency was found to be associated with the dissemination of mycobacterial disease, and its expression correlated with an effective immune and inflammatory response against mycobacteria in rodents as well as in human [15, 16]. Elevated levels of circulatory plasma OPN [17] and low levels of leptin [18] were reported to be associated with active tuberculosis; these biomarkers served as a negative evidence of active disease.

2. Materials and Methods

2.1. Study Subjects. A case-control study was conducted between March and October of 2010 in adult participants (age $>$ 18 years) in the Philippines. Thirty-one healthy, adult healthcare workers (HCWs) without any concomitant symptoms or chest radiographic findings relevant to active TB and who had negative HIV serology were recruited from San Lazaro Hospital (SLH), Manila, Philippines. Fifty-six newly diagnosed, asymptomatic HIV carriers (HIV-AC) without any clinical symptoms relevant to tuberculosis were randomly selected from among patients receiving care at the outpatient department of the SLH. None of the subjects took any anti-HIV therapy. Subjects with AIDS-defining events, currently active tuberculosis, or any symptoms relevant to tuberculosis, other than active pulmonary

diseases, underlying malignancy or metabolic disorders were excluded from the study. The exclusion criteria for active tuberculosis were based on both clinical findings and chest X-ray (CXR) findings in the HCWs. The study was approved by the ethics committee of SLH and the Tohoku University Hospital. We obtained written informed consent from all the participants. Three mL of blood was obtained directly (one mL in each tube) from each participant to perform the QFT assay. Simultaneously, plasma was separated from blood by centrifugation after treatment with EDTA and was aliquoted to CryoTubes for storage at -80°C until further utilization. All the procedures were conducted in accordance with the Helsinki declaration.

2.2. TBGL-Antibody Assay. TBGL-IgG antibody and -IgA antibodies were measured using the Determiner TBGL Antibody ELISA kit (Kyowa Medex, Tokyo, Japan), an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of anti-TBGL-IgG and -IgA in plasma. This assay employs glycolipid antigens purified from *M. tuberculosis* H37Rv (TBGL antigen) coated on a 96-well plate. The details of the assay were described in our previous study [8]. The antibody titers for TBGL-IgG and -IgA were expressed as U/mL. Positive TBGL-IgG titers were determined according to the cutoff index proposed by Kishimoto et al. [19]. The samples were classified as positive when the serum levels of anti-TBGL-IgG were ≥ 2 U/mL. An arbitrary cutoff value of ≥ 2 U/mL for TBGL-IgA was used according to the unpublished data of our previous study [8].

2.3. QuantiFERON-TB Gold In-Tube (QFT). The QFT test was performed using fresh whole blood in accordance with the manufacturer's instruction (Cellestis, Australia). The results were interpreted using specific software provided by Cellestis. The result was scored positive if the IFN- γ concentration in the tube TB-specific antigen containing was >0.35 IU/mL after subtracting the value of the nil control (IFN- γ -nc) and at least $>25\%$ of NC value. If the net IFN- γ response (TB Ag minus nil) was <0.35 IU/mL for the antigens and the response to the mitogen-positive control was >0.5 IU/mL, the response was considered as test negative. An intermediate result was recorded if the net IFN- γ response was <0.35 IU/mL for the antigen and <0.5 IU/mL for the mitogen and/or was above 8 IU/mL for the NC.

2.4. Leptin and OPN Elisa Assay. Plasma leptin levels were determined by sandwich ELISA using Quantikine Human Leptin Immunoassay kit (R&D Systems) for the quantitative determination of the human leptin concentrations in plasma according to the manufacturer's guidelines. Plasma OPN concentrations were determined using Human OPN Elisa kit (Immuno-Biological Laboratories, Takasaki, Japan) according to the manufacturer's guidelines, and values were expressed as ng/mL.

2.5. Clinical Data. We measured different laboratory markers including complete red blood cell counts, the number of white blood cells with their differential counts, levels of

hemoglobin, and serum levels of IgG and IgA. The number of CD4+ T cell counts and HIV RNA load of HIV-AC were also determined.

2.6. Statistical Analysis. The data of quantitative variables are summarized as median and range. Categorical variables were computed as frequency and percentage. The data were analyzed using Stat Flex software, version 5 (Artech Co., Ltd: <http://www.statflex.net/index.html>) and Statcel 2 (OMS Publishing Inc. Saitama, Japan). The ability of each single marker to discriminate HIV from HCW by receiver operating characteristic (ROC) curve and the area under curve (AUC) was also analyzed. The percentage of overall agreement between QFT and TBGL-IgG/IgA ELISA assays was calculated, and a Cohen's Kappa coefficient was used to assess the level of agreement. The significance of association for categorical variables was estimated by Fisher's exact test, whereas correlations between continuous variables were evaluated by Spearman's rank correlation coefficient. The differences in significance between continuous variables were compared by the Mann-Whitney *U* test. A 2-tailed *P* value of <0.05 was considered significant.

3. Results

3.1. Characteristics of Study Participants. A total of 31 HCWs and 56 newly diagnosed HIV-AC were enrolled in the current study. Basic demographic and clinical characteristics of the study participants are shown in Table 1. The participating HIV-AC were relatively young ($P = 0.03$) with a significant male predominance ($P < 0.0001$) compared to the HCWs. Although lymphocyte counts were comparable between the two groups, total counts of WBC, neutrophils, and monocytes were significantly lower in HIV-AC.

3.2. QFT and TBGL-Antibody Assays in HCWs. Forty-eight percent (15/31) of the HCWs showed positive reactions in the QFT assay indicating high incidences of LTBI (Table 1). The median age of the QFT-positive responders from among the HCWs were significantly higher than those of the QFT-negative group ($P = 0.002$). TBGL-IgG and TBGL-IgA were positive in 51% and 19% of HCWs, respectively (Table 1).

Eleven of 15 (73%) QFT-positive HCWs had positive TBGL-IgG responses (categorical agreement 73%), whereas 5 of 16 (31%) QFT-negative subjects had positive TBGL-IgG responses (categorical agreement 68.7%). The overall κ value was 0.42, indicating a moderate association between the two assays (overall agreement: 71%; 95% CI: 0.10~0.73). The TBGL-IgG-positive proportions were also significantly different between QFT-positive and QFT-negative groups of HCWs ($P = 0.02$). Although the number of positive TBGL-IgA responders was small in HCWs and failed to show any significant difference ($P = 0.072$), the TBGL-IgG+IgA double-positive response was shown only by QFT-positive HCWs and none of the QFT-negative HCWs had double-positive reactions ($P = 0.043$) (Figure 1) (Table 2).

In addition, significant positive correlation was observed between the concentrations of IFN- γ -nc and TBGL-IgA




FIGURE 1: Positivity percentage of TBGL-IgG/IgA assay in QFT-positive/negative healthcare workers. The level of agreement between QFT and the TBGL-Ab assay was measured by Cohen's kappa (κ). $\kappa = 0.42$; overall agreement 71%; 95% confidence interval: 0.1~0.73. *Significant difference ($P < 0.05$).

titers in the QFT-positive group ($r = 0.74$, $P = 0.005$) (Figure 2), but not in the QFT-negative group. There was no such association between IFN- γ -nc and TBGL-IgG levels in HCWs, although a tendency for a positive correlation was observed in the QFT-positive HCWs ($r = 0.43$, $P = 0.11$) (Figure 2). No association was observed in the net IFN- γ concentrations in antigen-stimulated QFT-plasma with TBGL-IgG or -IgA titers (data not shown). The plasma levels of OPN and leptin were not different between QFT-positive and QFT-negative HCWs (Table 2).

3.3. QFT and TBGL-Antibody Assays in HIV-AC. As shown in Table 1, only 13 of 56 (23%) HIV carriers showed positive reactions by QFT assay. The rate of positivity was closely associated with high median CD4+ T cell counts ($P = 0.012$) and younger age ($P = 0.036$) (Table 2). Seven of 56 (12.5%) HIV-AC who had lower mitogen responses (IFN- γ concentrations: median: 1.78 IU/mL; range: 0.38~6.73 IU/mL) than the rest (>10 IU/mL) had negative responses by QFT assay. Their median CD4+ T-cell counts were 60/ μ L (range: 43~425/ μ L) (data not shown). Thirty-three of 56 (59%) and 16 of 56 (29%) HIV-AC were attributed with positive TBGL-IgG and TBGL-IgA responses, respectively (Table 1). The positive proportions of TBGL-IgG and -IgA responses were not significantly different between QFT-positive and -negative HIV-AC (Table 2). However, 6 of 7 QFT-negative low mitogen responders in HIV-AC were positive for both TBGL-IgG and -IgA assay (data not shown). The TBGL-IgA titers were significantly higher in the TBGL-IgG-positive HIV-AC ($P = 0.041$) (Table 3). In addition, TBGL-IgA-positive HIV-AC had significantly elevated titers of TBGL-IgG ($P = 0.042$), serum IgA ($P = 0.015$), and OPN ($P = 0.03$), (Table 3). Interestingly, the TBGL-IgA-positive proportion was inversely correlated with the CD4+ T-cell counts ($P = 0.018$), and the titers were significantly higher in the HIV-AC with CD4+ T-cell count < 350/ μ L

TABLE 1: Demographic and clinical data of study participants.

Variables	HCWs (n = 31)	HIV-AC (n = 56)	P
Demographic data			
Gender: male; n (%)	16 (51.6)	55 (96.5)	<0.0001*
Age year; median (range)	35 (19~62)	28 (19~48)	0.03*
Laboratory findings [†]			
Hemoglobin (g/dL)	13.2 ± 2.6	13 ± 1.49	0.36
RBC (million/ μ L)	4.96 ± 1.6	4.43 ± .55	0.069
WBC (10^3 / μ L)	7.5 ± 2.5	5.9 ± 1.9	0.01*
Neutrophil (10^3 / μ L)	4.4 ± 2.2	3.3 ± 1.2	0.048*
Lymphocyte (10^3 / μ L)	2.4 ± 0.6	2.2 ± 0.9	0.82
Monocyte (/ μ L)	562 ± 237	338 ± 182	<0.001*
CD4+ T-cell count (/ μ L)	ND	443 ± 286	NA
QFT assay positive; n (%)	15 (48)	13 (23)	0.03*
TBGL-IgG positive; n (%)	16 (51)	33 (59)	0.9
TBGL-IgA positive; n (%)	6 (19)	16 (29)	0.87
IFN- γ -nc (IU/mL)	0.42 ± 0.96	0.13 ± 0.11	<0.001*
TBGL-IgG (U/mL)	3.12 ± 3.36	3.94 ± 6.63	0.14
TBGL-IgA (U/mL)	1.68 ± 2.56	3.1 ± 6.64	0.012*
Serum IgG (mg/dL)	1409 ± 212	1391 ± 224	0.49
Serum IgA (mg/dL)	246 ± 92	319 ± 138	0.058
OPN (ng/mL)	14.4 ± 11	159 ± 191	<0.00001*
Leptin (ng/mL)	18.6 ± 13.9	7.2 ± 5.4	<0.001*

Abbreviations: HCWs, healthcare workers; HIV-AC, newly diagnosed cases of asymptomatic human immune-deficiency virus infection; OPN, osteopontin; ND, not determined; NA, not applicable.

[†] values were presented as mean \pm SD unless indicated otherwise; IFN- γ -nc: levels of IFN- γ , measured in the nonstimulated QFT-plasma samples; P values for statistical differences between HCW and HIV-AC; *significant differences ($P < 0.05$).

TABLE 2: Comparison between QFT-positive and QFT-negative HCWs and HIV-AC.

Variables	HCWs			HIV-AC		
	QFT+ (n = 15)	QFT- (n = 16)	P	QFT+ (n = 13)	QFT- (n = 43)	P
Age; median (range)	45 (21~62)	23.5 (19~48)	0.002*	25 (19~45)	31 (21~35)	0.036*
Gender: male; n (%)	7 (46.6)	9 (47.4)	0.43	12 (92.3)	42 (97.67)	0.43
Work duration->10 yrs; n (%)	11(73.3)	6 (37.5)	0.098	NA	NA	NA
CD4+ count (/ μ L); median (range)	ND	ND	NA	611 (148~1466)	356 (13~1125)	0.012*
TBGL-IgG positive; n (%)	11 (73)	5 (31)	0.02*	8 (61.5)	25 (58.13)	0.545
TBGL-IgA positive; n (%)	5 (33)	1 (6)	0.072	3 (23)	13 (30)	0.415
TBGL-IgG+IgA positive; n (%)	4 (27)	0 (0)	0.043*	2(15.4)	10 (23.3)	0.42
IFN- γ -nc (IU/mL) [†]	0.3 ± 0.4	0.2 ± 0.13	0.9	0.21 ± 0.17	0.1 ± 0.07	0.0087*
Serum IgG (mg/dL) [†]	1450 ± 188	1368 ± 235	0.2	1306 ± 207	1414 ± 249	0.5
Serum IgA (mg/dL) [†]	268 ± 81	225 ± 101	0.32	330 ± 130	312 ± 138	0.68
OPN (ng/mL) [†]	14.5 ± 11.2	14.2 ± 11.2	0.87	115.4 ± 130	173.2 ± 203	0.43
Leptin (ng/mL) [†]	21.3 ± 13.3	15.9 ± 14.3	0.25	6.46 ± 4.12	7.448 ± 5.68	0.24

Abbreviations: HCWs, healthcare workers; HIV-AC, newly diagnosed cases of asymptomatic human immune-deficiency virus infection; OPN, osteopontin; ND, not determined; NA, not applicable.

[†] mean \pm SD; IFN- γ -nc: levels of IFN- γ , measured in the nonstimulated QFT-plasma samples; P values for statistical differences between QFT-positive and QFT-negative groups; *significant differences ($P < 0.05$).




FIGURE 2: Correlations between TBGL-IgA or TBGL-IgG titers and IFN- γ concentrations measured in nonstimulated QFT-plasma samples (IFN- γ -nc) in QFT-positive/QTF-negative healthcare workers (HCWs) and asymptomatic HIV carriers (HIV-AC). The only significant positive correlation was observed between the IFN- γ -nc concentrations and TBGL-IgA titers in the QFT-positive HCW group ($r = 0.74$, $P = 0.005$).

(HIV-LCD) ($P = 0.048$) (Table 4). Furthermore, in the HIV-AC, a relatively higher proportion of double positive (TBGL-IgG+IgA) responders was found in the HIV-LCD group (29%) than in the HIV-HCD group ($CD4+$ count $\geq 350/\mu L$) (16%), although the difference was not statistically significant ($P = 0.32$) (Table 4).

Moreover, the IFN- γ -nc concentrations were significantly lower in the QFT-negative HIV-AC ($P = 0.008$)

(Table 2). No association was observed between the IFN- γ -nc concentrations and TBGL-IgG or -IgA titers in any group of HIV-AC (Figure 2). The plasma levels of OPN and leptin were not different between QFT-positive and QTF-negative HIV-AC (Table 2).

3.4. Comparison between the Serum Antibodies and TBGL Antibodies. The TBGL-IgG and -IgA had no correlation with

TABLE 3: Comparison between TBGL-IgG or TBGL-IgA-positive and -negative HIV-AC.

Variables	TBGL-IgG			TBGL-IgA		
	Positive (n = 33)	Negative (n = 23)	P	Positive (n = 16)	Negative (n = 40)	P
Age; median (range)	28 (19~48)	30 (19~41)	0.18	31.5 (19~48)	28 (19~45)	0.038*
Gender: male; n (%)	33 (100)	21 (91.3)	0.43	16 (100)	38 (95)	1
CD4 count (/μL); mean (range)	436 (13~1466)	450 (60~851)	0.45	346 (46~1125)	480 (13~1466)	0.06
QFT positive; n (%)	8 (24.2)	5 (21.7)	0.545	3 (19)	10 (25)	0.45
TBGL-IgA positive; n (%)	12 (36.4)	4 (17.4)	0.1	—	—	—
TBGL-IgG positive; n (%)	—	—	—	12 (75)	21 (52.5)	0.14
IFN-γ-nc (IU/mL) [†]	0.13 ± 0.09	0.1 ± 0.05	0.4	0.12 ± 0.09	0.12 ± 0.07	0.9
TBGL-IgA (U/mL) [†]	4.36 ± 8.4	1.28 ± 1.21	0.041*	—	—	—
TBGL-IgG (U/mL) [†]	—	—	—	7.5 ± 11.6	2.5 ± 1.5	0.042*
Serum IgG (mg/dL) [†]	1439 ± 277	1515 ± 677	0.5	1615 ± 404	1355 ± 135	0.46
Serum IgA (mg/dL) [†]	277 ± 95	279 ± 74	0.37	410 ± 165	313 ± 138	0.015*
OPN (ng/mL) [†]	176.3 ± 199.9	136 ± 172.5	0.67	280 ± 275	115 ± 109.7	0.03*
Leptin (ng/mL) [†]	7.33 ± 6.16	7.18 ± 4.12	0.68	7.33 ± 6.16	7.18 ± 4.12	0.07

Abbreviations: HIV-AC, newly diagnosed cases of asymptomatic human immune-deficiency virus infection; OPN, osteopontin.

[†] mean ± SD; IFN-γ-nc: levels of IFN-γ, measured in the nonstimulated QFT-plasma samples; P for statistical differences between QFT-positive and QFT-negative groups; *significant differences (P < 0.05).

TABLE 4: Comparison between HIV-AC with high[§] and low[‡] CD4+ T-cell count.

Variables	CD4+ high [§] (n = 32)	CD4+ low [‡] (n = 24)	P value [¶]
Age; mean (range)	25.5 (19~45)	25 (22~48)	0.018*
Gender: male; n (%)	31 (97)	23 (98)	1.0
CD4+ count (/μL); median (range)	618 (356~1466)	201 (13~349)	<0.001 ⁺
QFT-positive; n (%)	10 (31)	3 (12.5)	0.12
TBGL-IgG positive; n (%)	16 (50)	16 (67)	0.27
TBGL-IgA positive; n (%)	5 (16)	11 (46)	0.018*
TBGL-IgG+ IgA positive; n (%)	5 (16)	7 (29)	0.32
IFN-γ-nc (IU/mL)	0.14 ± 0.12	0.13 ± 0.09	0.9
TBGL-IgG (U/mL) [†]	4.6 ± 8.4	3 ± 2.8	0.59
TBGL-IgA (U/mL) [†]	1.55 ± 2	5.16 ± 9.6	0.048*
Serum IgG (mg/dL) [†]	1352 ± 185	1549 ± 380	0.5
Serum IgA (mg/dL) [†]	265 ± 89	423 ± 149	<0.001*
OPN (ng/mL) [†]	119 ± 126	214 ± 246	0.19
Leptin (ng/mL) [†]	7.7 ± 6	6.6 ± 4.9	0.5

Abbreviation: HIV-AC, newly diagnosed cases of asymptomatic human immune-deficiency virus infection; OPN: osteopontin.

[§] High: CD4+ T cell count ≥ 350/μL; [‡] low: CD4+ T-cell count < 350/μL; [†] mean ± SD; IFN-γ-nc: levels of IFN-γ, measured in the non-stimulated QFT-plasma samples; P values for statistical differences between QFT-positive and QFT-negative groups; *significant differences (P < 0.05).

the serum IgG and IgA in HCW and HIV-AC except for the association between the serum IgA levels and the TBGL-IgA titers in HIV-AC (P = 0.02) (data not shown).

3.5. Comparison of Biomarkers between HCW and HIV-AC. The levels of IFN-γ-nc (P < 0.001) were significantly higher in HCWs than in HIV-AC. However, the titers of TBGL-IgA

(P = 0.012), but not -IgG, were significantly higher in HIV-AC than in HCWs. Similarly, the serum IgA levels were also higher (P = 0.058). The OPN levels were significantly higher (P < 0.0001), and the leptin levels were considerably lower (P < 0.001) in the HIV-AC compared to the HCWs (Table 1).

ROC curve analysis was used to discriminate HIV from HCW groups using the net IFN-γ, leptin, and plasma levels




FIGURE 3: Receiver operating characteristic analysis for comparison of biomarkers between healthcare workers and asymptomatic HIV carriers. The result showed that the OPN plasma levels of OPN (log) exhibited the greatest ability to discriminate HIV from HCWs based on the AUC (0.883), followed by leptin (0.763) and net IFN- γ (0.648).

of OPN (log) as biomarkers. As shown in Figure 3, the plasma levels of OPN (log) exhibited the greatest ability to discriminate HIV from HCWs based on the AUC (0.883), followed by leptin (0.763) and net IFN- γ (0.648). However, QFT assay as well as TBGL-IgA and -IgG did not show such profiles (data not shown).

4. Discussion

In our data, the application of QFT assay to HCWs in the Philippines demonstrated a high incidence (48%) of LTBI, which was comparable to other already published data in HCWs in TB-endemic developing countries [4]. The increased risk of LTBI among HCWs was confirmed by the recent introduction of IGRA [20, 21]. In our country, a higher incidence of LTBI in HCWs was reported in high-risk groups for TB, such as homeless areas [22], compared to other areas [23].

We aimed to clarify the relationship between the TBGL-IgG and -IgA responses and that of IFN- γ in the QFT assay in LTBI. The rate of TBGL-IgG positivity was significantly higher in the QFT-positive than QFT-negative group of HCWs. The significant association between the two assay systems indicated by the κ value in HCWs demonstrated the TBGL-IgG in LTBI. However, about 30% of QFT-positive populations from among the HCWs lacked TBGL-IgG, and 30% of those of the QFT-negative group have elevated TBGL-IgG antibody, and the discordant cases were higher in TBGL-IgA. However, the reasons for such discordances between the two systems in HCWs are not clear. It is possible that the generation of antibody requires larger amounts of antigens

than does the generation of T-cell responses. Although associated immunosuppressive conditions were found as risk factors for false-negative QFT responses [24], such cases were excluded from HCWs in our study.

The mechanism of the synthesis of anti-TDM antibody is not clear, though TDM is known to bind to Mincle (macrophage-inducible C-type lectin) that is present on macrophages [25], and upon the activation, on T cells [26]. It was found that Mincle is specific for the ester linkage of a fatty acid to the trehalose, which explains the strong binding of TDM, but not trehalase-treated TDM, soluble trehalose, or purified mycolate [26]. The conversion of TDM into glucose monomycolate (GMM) upon mycobacterial infection might be the mechanism by which mycobacteria escape from the Mincle-mediated immunity. However, the immune system possesses other tools to monitor and eliminate live mycobacteria through CD1 molecules expressed on the activated macrophages and dendritic cells, which are different from MHC I, II molecules. Recently, GMM but not TDM was demonstrated to interact with CD1b and may induce adaptive immunity [27]. Although it is not known whether the adaptive immune system leads to antibody synthesis, the generated antibody may recognize both TDM and GMM because the two molecules are structurally very similar.

Interestingly, the IFN- γ -nc levels that were observed to have a significant association with the TBGL-IgA titers in LTBI of HCWs. IgA is a typical marker of the mucosal immune response. An elevated serum IgA has been proposed to have a protective role in IFN- γ -positive immunocompetent LTBI individuals [28]. Frequent exposure to tubercle bacilli can possibly stimulate the mucosal immune system in TB-endemic countries. It is also known that commensal bacteria on the mucosal surface induce IgA in an NO-dependent manner [29], although it is not known whether MTB in LTBI has a similar effect in lung mucosa. Circulating glycolipid immune complexes might lead to nonspecific stimulation of T cells, but a component of TBGL, TDM, could also enhance the *in vivo* production of IL-12p40 and IFN- γ in mouse model [30]. IgA antibody and IFN- γ induce TNF- α and NO production, which mediated the inhibitory mechanism for *M. tuberculosis* infection in mouse model [28]. Furthermore, there is strong evidence of a synergic effect between IgA and IFN- γ in bactericidal activities against MTB infection [31]. Therefore, the association between anti-TBGL-IgA and IFN- γ may indicate protective, mucosal immune activities in LTBI in HCWs.

In HIV carriers, the QFT-positive responses were significantly lower than in HCWs and were greatly dependent on the high CD4+ T-cell counts in the present study. Much evidence suggests that the baseline CD4+ T-cell count is a determining factor for a positive QFT response in HIV infection [32]. Since HIV infection is a disease of immune deficiency, immune deprivation may be less prominent in relatively young QFT-positive cases because IFN- γ could be synthesized properly by stimulation with the appropriate signals. In contrast, the response could be altered in advance immune-deficiency state, as indicated by low CD4+ T-cell counts. Therefore, it is expected that

significant numbers of false-negative reactions are present in QFT-negative HIV carriers. The relatively low IFN- γ levels by mitogen stimulation in some of the QFT-negative responders also support this possibility. Therefore, for TB diagnosis in advanced immunosuppression, the ratio of the IFN- γ response/CD4+ T-cell count Elispot assay was suggested to improve the sensitivity of the assay [33].

It is not clear why HIV infection does not diminish the TBGL antibody titers. It is known that the CD-1 presentation pathway persists in patients with HIV, but antiglycolipid antibodies were found to have no relationship with the TST results [34] or bacillary yield [35]. Similarly, we did not find any correlation between the QFT result and anti-TBGL antibodies. It is also possible that concomitant non-TB mycobacterium infection may stimulate the TBGL antibody synthesis in HIV-AC [7]. Significant numbers of HIV carriers have antibodies to TBGL, but we could not confirm if they indicate LTBI or not.

The increases of serum IgA in advanced HIV infection and of IgG in the early stage were already reported [36]. Although specific antibody titers in HIV infection are decreased by some infectious agents including hepatitis B virus but not in hepatitis A virus, probably because of alterations in the immune systems in advanced HIV infection [37], it is not known whether nonfunctional or functional IgA was synthesized in our cases. The main limitation of the current study is the small number of study subjects and the lack of a follow-up study for estimating the risk of developing active tuberculosis.

Finally, to determine the correlations between biomarkers in infected states, we evaluated data by ROC curve analysis (Figure 3). In this study, the plasma levels of OPN were most specific to HIV and the levels were not elevated in LTBI HCWs (Figure 3, Table 2). Therefore the levels can be a good marker for active TB in non-HIV individuals, because the OPN is known as a marker of active TB [17]. In HIV-AC, the OPN plasma levels are already elevated as described here, and it was already reported that the levels further increase when they developed active TB [38, 39]. It is also known that interferon-inducible protein-10 (IP-10) and IL-18 were elevated in HIV/TB patients than in HIV patients and suggested to be helpful in monitoring the treatment for patients [38]. All these biomarkers were mainly produced by macrophages, and it was also reported that OPN is synthesized by macrophages as well as CD4+ T cells in HTLV-1-induced lymphoma [40, 41].

In this study we noted elevations of anti-TBGL antibody in LTBI in HCWs, but no link between the elevations with LTBI in HIV-AC was confirmed, probably due to the inflammatory conditions in HIV.

5. Conclusion

We have found the elevation of TBGL-IgG titers in LTBI in HCWs. In addition, the association between TBGL-IgA and IFN- γ in HCWs was found, and it was hypothesized that the mucosal immunity is involved in LTBI in HCWs. We could not find any relationships between QFT and TBGL in HIV-AC. Low CD4+ cell count was associated with inflammatory

conditions as represented by high OPN in HIV-AC, which may be the reason for ambiguous results.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors' Contribution

US and PL did experiments using the samples and contributed equally as the first author. HCY and BS contributed to the experimental system and statistical analysis. HS and YA and YS contributed to the planning and proposal of the work. TH and ET coordinated the work.

Acknowledgments

The authors are thankful to all healthcare workers and HIV carriers who participated in this study. Sincere appreciation also goes to Ms. Mizuho Kawamura from Kyowa Medex Co Ltd, Japan, for providing the anti-TBGL-Ab ELISA kits. This work was supported by Grant-in-Aid for Scientific Research from JSPS and the Scientific Research Expenses for Health and Welfare Program from the Ministry of Health and Welfare, Japan. Financial support for this study was also provided by the Health Labor Sciences Research Grant 20-005-OH from the Ministry of Health, Labor, and Welfare, Japan. The authors are also grateful for international collaborative study grants from the Human Science Foundation and Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Cultural, Sports, Science and Technology, Japan.

References

- [1] World Health Organization, *Global Tuberculosis Control: WHO Report 2011*, WHO/HTM/TB/2011.16, World Health Organization, Geneva, Switzerland, 2011.
- [2] L. J. Abu-Raddad, L. Sabatelli, J. T. Achterberg et al., "Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 33, pp. 13980–13985, 2009.
- [3] M. Pai, A. Zwerling, and D. Menzies, "Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update," *Annals of Internal Medicine*, vol. 149, no. 3, pp. 177–184, 2008.
- [4] D. Menzies, R. Joshi, and M. Pai, "Risk of tuberculosis infection and disease associated with work in health care settings," *International Journal of Tuberculosis and Lung Disease*, vol. 11, no. 6, pp. 593–605, 2007.
- [5] I. Latorre, X. Martinez-Lacasa, R. Font et al., "IFN- γ response on T-cell based assays in HIV-infected patients for detection of tuberculosis infection," *BMC Infectious Diseases*, vol. 10, no. 348, 2010.
- [6] R. K. Verma and A. Jain, "Antibodies to mycobacterial antigens for diagnosis of tuberculosis," *FEMS Immunology and Medical Microbiology*, vol. 51, no. 3, pp. 453–461, 2007.
- [7] R. Maekura, Y. Okuda, M. Nakagawa et al., "Clinical evaluation of anti-tuberculous glycolipid immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis,"

- Journal of Clinical Microbiology*, vol. 39, no. 10, pp. 3603–3608, 2001.
- [8] M. Mizusawa, M. Kawamura, M. Takamori et al., "Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis," *Clinical and Vaccine Immunology*, vol. 15, no. 3, pp. 544–548, 2008.
 - [9] U. R. Siddiqi, W. Punpunich, C. Chuchottaworn et al., "Elevated anti-tubercular glycolipid antibody titers in healthy adults as well as in pulmonary TB patients in Thailand," *The International Journal of Tuberculosis and Lung Disease*. In press.
 - [10] S. Nabeshima, M. Murata, K. Kashiwagi, M. Fujita, N. Furusyo, and J. Hayashi, "Serum antibody response to tuberculosis-associated glycolipid antigen after BCG vaccination in adults," *Journal of Infection and Chemotherapy*, vol. 11, no. 5, pp. 256–258, 2005.
 - [11] S. D. Lawn and G. Churchyard, "Epidemiology of HIV-associated tuberculosis," *Current Opinion in HIV and AIDS*, vol. 4, no. 4, pp. 325–333, 2009.
 - [12] J. P. Narain and Y. R. Lo, "Epidemiology of HIV-TB in asia," *Indian Journal of Medical Research*, vol. 120, no. 4, pp. 277–289, 2004.
 - [13] V. Sánchez-Margalet, C. Martín-Romero, J. Santos-Alvarez, R. Goberna, S. Najib, and C. Gonzalez-Yanes, "Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action," *Clinical and Experimental Immunology*, vol. 133, no. 1, pp. 11–19, 2003.
 - [14] T. Uede, Y. Katagiri, J. Iizuka, and M. Murakami, "Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein?" *Microbiology and Immunology*, vol. 41, no. 9, pp. 641–648, 1997.
 - [15] G. J. Nau, G. L. Chupp, J. F. Emile et al., "Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection," *American Journal of Pathology*, vol. 157, no. 1, pp. 37–42, 2000.
 - [16] G. J. Nau, L. Liaw, G. L. Chupp, J. S. Berman, B. L. M. Hogan, and R. A. Young, "Attenuated host resistance against *Mycobacterium bovis* BCG infection in mice lacking osteopontin," *Infection and Immunity*, vol. 67, no. 8, pp. 4223–4230, 1999.
 - [17] Y. Koguchi, K. Kawakami, K. Uezu et al., "High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis," *American Journal of Respiratory and Critical Care Medicine*, vol. 167, no. 10, pp. 1355–1359, 2003.
 - [18] R. van Crevel, E. Karyadi, M. G. Netea et al., "Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation," *Journal of Clinical Endocrinology and Metabolism*, vol. 87, no. 2, pp. 758–763, 2002.
 - [19] T. Kishimoto, O. Moriya, J. I. Nakamura, T. Matsushima, and R. Soejima, "Evaluation of the usefulness of a serodiagnosis kit, the determiner TBGL antibody for tuberculosis: setting reference value," *Kekkaku*, vol. 74, no. 10, pp. 701–706, 1999.
 - [20] A. Zwerling, S. van den Hof, J. Scholten, F. Cobelens, D. Menzies, and M. Pai, "Interferon- γ release assays for tuberculosis screening of healthcare workers: a systematic review," *Thorax*, vol. 67, no. 1, pp. 62–70, 2012.
 - [21] A. Nienhaus, A. Schablon, C. Le Bâcle, B. Siano, and R. Diel, "Evaluation of the interferon- γ release assay in healthcare workers," *International Archives of Occupational and Environmental Health*, vol. 81, no. 3, pp. 295–300, 2008.
 - [22] T. Tabuchi, T. Takatorige, Y. Hirayama et al., "Tuberculosis infection among homeless persons and caregivers in a high-tuberculosis-prevalence area in Japan: a cross-sectional study," *BMC Infectious Diseases*, vol. 11, no. 22, 2011.
 - [23] N. Harada, Y. Nakajima, K. Higuchi, Y. Sekiya, J. Rothel, and T. Mori, "Screening for tuberculosis infection using whole-blood interferon- γ and Mantoux testing among Japanese healthcare workers," *Infection Control and Hospital Epidemiology*, vol. 27, no. 5, pp. 442–448, 2006.
 - [24] E. Y. Kim, M. S. Park, Y. S. Kim, S. K. Kim, J. Chang, and Y. A. Kang, "Risk factors for false-negative results of QuantiFERON-TB gold in-tube assay in non-HIV-infected patients with culture-confirmed tuberculosis," *Diagnostic Microbiology and Infectious Disease*, vol. 70, no. 3, pp. 324–329, 2011.
 - [25] M. Matsumoto, T. Tanaka, T. Kaisho et al., "A novel LPS-inducible C-type lectin is a transcriptional target of NF- κ B in macrophages," *Journal of Immunology*, vol. 163, no. 9, pp. 5039–5048, 1999.
 - [26] E. Ishikawa, T. Ishikawa, Y. S. Morita et al., "Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle," *Journal of Experimental Medicine*, vol. 206, no. 13, pp. 2879–2888, 2009.
 - [27] I. Matsunaga, T. Naka, R. S. Talekar et al., "Mycolytransferase-mediated glycolipid exchange in mycobacteria," *Journal of Biological Chemistry*, vol. 283, no. 43, pp. 28835–28841, 2008.
 - [28] R. Z. Topić, S. Dodig, and I. Zoričić-Letoja, "Interferon- γ and immunoglobulins in latent tuberculosis infection," *Archives of Medical Research*, vol. 40, no. 2, pp. 103–108, 2009.
 - [29] H. Tezuka, Y. Abe, M. Iwata et al., "Regulation of IgA production by naturally occurring TNF/ iNOS -producing dendritic cells," *Nature*, vol. 448, no. 7156, pp. 929–933, 2007.
 - [30] I. P. Oswald, C. M. Dozois, J. F. Petit, and G. Lemaire, "Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages," *Infection and Immunity*, vol. 65, no. 4, pp. 1364–1369, 1997.
 - [31] R. Reljic, A. Williams, and J. Ivanyi, "Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?" *Tuberculosis*, vol. 86, no. 3–4, pp. 179–190, 2006.
 - [32] A. Fujita, A. Ajisawa, N. Harada, K. Higuchi, and T. Mori, "Performance of a whole-blood interferon-gamma release assay with mycobacterium RD1-specific antigens among HIV-infected persons," *Clinical and Developmental Immunology*, vol. 2011, Article ID 325295, 2011.
 - [33] T. Oni, J. Patel, H. P. Gideon et al., "Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts," *European Respiratory Journal*, vol. 36, no. 3, pp. 594–600, 2010.
 - [34] H. L. David, F. Papa, P. Cruaud et al., "Relationships between titers of antibodies immunoreacting against glycolipid antigens from *Mycobacterium leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis," *International Journal of Leprosy*, vol. 60, no. 2, pp. 208–224, 1992.
 - [35] N. Simonney, P. Chavanet, C. Perronne et al., "B-cell immune responses in HIV positive and HIV negative patients with tuberculosis evaluated with an ELISA using a glycolipid antigen," *Tuberculosis*, vol. 87, no. 2, pp. 109–122, 2007.
 - [36] J. A. Fling, J. R. Fischer Jr, R. N. Boswell, and M. J. Reid, "The relationship of serum IgA concentration to human

- immunodeficiency virus (HIV) infection: a cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force," *Journal of Allergy and Clinical Immunology*, vol. 82, no. 6, pp. 965–970, 1988.
- [37] S. Perry, R. Hussain, and J. Parsonnet, "The impact of mucosal infections on acquisition and progression of tuberculosis," *Mucosal Immunology*, vol. 4, no. 3, pp. 246–251, 2011.
- [38] C. Ridruechai, S. Sakurada, H. Yanai et al., "Association between circulating full-length osteopontin and IFN- γ with disease status of tuberculosis and response to successful treatment," *Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 42, no. 4, pp. 876–889, 2011.
- [39] H. Chagan-Yasutan, H. Saitoh, Y. Ashino et al., "Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy," *Tohoku Journal of Experimental Medicine*, vol. 218, no. 4, pp. 285–292, 2009.
- [40] D. D. Taub, A. R. Lloyd, K. Conlon et al., "Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells," *Journal of Experimental Medicine*, vol. 177, no. 6, pp. 1809–1814, 1993.
- [41] H. Chagan-Yasutan, K. Tsukasaki, Y. Takahashi et al., "Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia," *Leukemia Research*, vol. 35, no. 11, pp. 1484–1490, 2011.

Distinct Clinical Features in Nontuberculous Mycobacterial Disease with or without Latent Tuberculosis Infection

Umme Ruman Siddiqi,¹ Haorile Chagan-Yasutan,³ Chie Nakajima,² Hiroki Saitoh,¹ Yugo Ashino,¹ Osamu Usami,¹ Beata Shiratori,³ Motoki Usuzawa,³ Yasuhiko Suzuki² and Toshio Hattori^{1,3}

¹Division of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan

²Department of Global Epidemiology, Research Centre for Zoonosis Control, Hokkaido University, Sapporo, Japan

³Disaster-related Infectious Diseases, Disaster Medical Science Division, International Research Institute of Disaster Science, Tohoku University, Sendai, Japan

Nontuberculous mycobacteria (NTM) diseases are in the face of a progressive increase even in immune-competent subjects, and the clinical features of NTM diseases are heterogenous. The decision to institute treatment of the patients should be made after a period of follow up, because therapy is often prolonged, and frequently ineffective. The reasons why some patients develop severe NTM diseases are not clear. Here we observed the involvement of latent tuberculosis infection (LTBI) in clinical and laboratory features of NTM diseases. We evaluated various tuberculosis-related inflammatory markers including osteopontin (OPN), pentraxin-3 (PTX-3), and soluble IL-2 receptor (sIL-2R) in NTM infected patients with or without LTBI. Eight NTM and 5 tuberculosis (TB) patients, and 5 healthy subjects were enrolled. Polymerase Chain Reaction (PCR) analysis confirmed the absence of tuberculosis specific gene (RD1 region), among clinical isolates from NTM patients. Interferon- γ (IFN- γ) release assay (IGRA) using Early Secreted Antigenic Target-6 (ESAT-6) and CFP-10, the RD1-encoded protein, was employed for determining LTBI. IGRA was positive in 4/8 NTM (NTM with LTBI, 50%) and 5/5 TB patients. Only 2 of 4 NTM with LTBI were under chemotherapy among all NTM patients, and others were followed up. The plasma levels of OPN, PTX3 and sIL-2R were significantly higher in NTM patients with LTBI than in those without LTBI ($P < 0.05$). The two patients under therapy showed the highest OPN levels that persisted after treatment. The increased inflammatory levels in NTM patients with LTBI indicate enhanced inflammatory reaction. Extensive therapy may be necessary in such patients.

Keywords: interferon- γ release assay; latent tuberculosis infection; nontuberculous mycobacterial disease; osteopontin; pentraxin-3

Tohoku J. Exp. Med., 2012, 226 (4), 313-319. © 2012 Tohoku University Medical Press

Infection caused by nontuberculous mycobacterium (NTM), especially by *Mycobacterium avium complex* (MAC), has been increasing in both immunocompromised and immunocompetent individuals in Japan and worldwide (Prince et al. 1989). MAC may cause progressive lung diseases leading to morbidity and mortality in previously healthy patients as well as in patients with pre-existing lung diseases and immunodeficiency (Griffith et al. 2007). Recently, it was reported that progressive lung disease due to MAC is associated with specific variable number of tandem repeat (VNTR) genotypes (Kikuchi et al. 2009) or with the clinical features of cavity formation (Ito et al. 2012). Lung disease due to NTM occurs commonly in structural lung diseases, such as chronic obstructive pulmonary dis-

ease (COPD), bronchiectasis, cystic fibrosis, pneumoconiosis, prior tuberculosis, pulmonary alveolar proteinosis, and esophageal motility disorders (Griffith et al. 2007). The detection of both *Mycobacterium tuberculosis* (MTB) and NTM by PCR in a patient was reported in Japan (Takeda et al. 2008) and most patients with MTB and MAC co-infection reported in USA were foreigners (Khan et al. 2010). NTM infection in Japan is frequently observed in elderly people, and elderly people are more frequently latently infected with MTB (LTBI) than young people in Japan and the Philippines (Siddiqi et al. in press), as confirmed by IFN- γ release assay (IGRA) and in Thailand, as confirmed by anti-tuberculous glycolipid (TBGL) assay (Siddiqi et al. 2012). Recently, several studies in different countries

Received February 23, 2012; revision accepted for publication March 26, 2012. doi: 10.1620/tjem.226.313

Correspondence: Toshio Hattori, Division of Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
e-mail: toshatto@med.tohoku.ac.jp

showed that the incidence of TB infections examined by IGRA (in most of the cases IGRA ELISA was used) was very low in NTM patients in MTB non-endemic countries (Van Leeuwen et al. 2007; Adams et al. 2008). In contrast, significant percentages of NTM were positive by IGRA in Taiwan and Korea (Wang et al. 2007; Ra et al. 2011). Given the variety of clinical courses of NTM, the effect of LTBI on the clinical and/or laboratory features of NTM should be evaluated.

It is well known that CD4 cells and Th1-mediated signaling molecules and their pathways are important in the defense against NTM infection (Griffith et al. 2007). Recently, it was found that osteopontin (OPN), a pro-inflammatory cytokine secreted by a wide variety of cells including T cells and macrophages and elevated in tuberculosis, is linked with CD4 T helper (Th1) cell lineage stimulation and was reported to regulate *Mycobacterium avium* in cattle (Karcher et al. 2008). It was also claimed that OPN expression correlates with effective immune and inflammatory responses in MAC-infected individuals (Nau et al. 2000). We also measured pentraxin-3 (PTX-3), which is associated with the acute-phase response and involved in innate immunity. PTX-3 is produced by mononuclear phagocytes, dendritic cells, and endothelial cells in response to inflammatory signals. PTX3 binds with high affinity to the complement and activates the classical pathway of complement and facilitates pathogen recognition by macrophages. (Garlanda et al. 2005; Inforzato et al. 2012). The plasma PTX-3 level, which was reported to reflect the degree of inflammation in MTB infection (Azzuri et al. 2005), can be highly expressed *in vitro* on human PBMCs and monocytes stimulated with lipoarabinomannan (LAM) (Vouret-Craviari et al. 1997).

The current study was designed to compare various serological markers that are associated with TB, including

OPN, PTX-3, leptin and soluble IL-2 receptor (sIL-2R), in NTM patients with or without LTBI to characterize their status.

Materials and Methods

Study population

All the patients that participated in this study were receiving care at Tohoku University Hospital between January 2008 and July 2010. We enrolled 9 patients (N1-9) who met the 2007 American Thoracic Society (ATS) microbiological criteria for pulmonary NTM diseases (Griffith et al. 2007). Six patients diagnosed as active TB (T1-6) were served as disease controls (Table 1). Among them, 2 patients (N7, T3) were withdrawn themselves from the study. NTM and MTB were confirmed from the site of infection by culture. In addition to culture, we repeatedly tested the samples from patients by PCR (Roche amplicon), and MTB was never detected in the NTM group. All the patients were assessed for clinical features, medical history including prior tuberculosis disease, treatment history and chest CT scan finding. Individuals with HIV/AIDS infection or who were receiving immunosuppressive therapy were excluded from the study. Five healthy volunteers who were without any symptoms relevant to active tuberculosis were enrolled as negative controls. The study was approved by the Ethics Committee of Tohoku University Hospital (2007-136; 2007-257). We obtained written informed consent from all the participants. All work was conducted in accordance with the Helsinki declaration. Plasma was obtained from EDTA-containing blood by centrifugation and was aliquoted to cryotubes and stored at -80°C for future use. Simultaneously, PBMCs were isolated over Ficoll-Paque Plus gradient and suspended in RPMI 1,640 supplemented with 2 mM L-glutamine, penicillin (100 U/ml), gentamycin (5 $\mu\text{g}/\text{ml}$) and 10% heat-inactivated FCS (Sigma) for further assay.

All the laboratory data including blood cell counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and sIL-2R were measured at Tohoku University Hospital.

Table 1. Patients profile and result of IFN- γ release assay (IGRA).

Patients ID	Gender	Age (yr)	Diagnosis	Mycobacteria	Duration of illness	IGRA
N1	M	79	NTM	<i>M. avium</i>	5 yrs	negative
N2	F	76	NTM	<i>M. avium</i>	5 yrs	positive
N3	F	62	NTM	<i>M. avium</i> , <i>M. intracellulare</i> , <i>M. fortuitum</i>	6 months	negative
N4	F	83	NTM	<i>M. avium</i>	7 yrs	negative
N5	F	68	NTM	<i>M. avium</i>	7 yrs	positive
N6	M	43	NTM	<i>M. abscessus</i>	6 months	positive
N8	M	61	NTM	<i>M. avium</i>	13 yrs	negative
N9	F	76	NTM	<i>M. intracellulare</i>	3 yrs	positive
T1	F	78	ETB	<i>M. tuberculosis</i>	2 months	positive
T2	F	71	ETB	<i>M. tuberculosis</i>	1 month	positive
T4	M	65	ETB	<i>M. tuberculosis</i>	1 month	positive
T5	F	32	ETB	<i>M. tuberculosis</i>	1 month	positive
T6	F	57	PTB	<i>M. tuberculosis</i>	1 month	positive

NTM, non-tuberculosis mycobacterium; ETB, extra-pulmonary tuberculosis, PTB, pulmonary tuberculosis.

RD1 PCR analysis

Mycobacterial isolates from 6 NTM patients were kindly provided by the central research laboratory of TUH. DNA was extracted from the clinical isolates as described previously (Nakajima et al. 2010). Briefly, glass beads (0.1 mm), the mycobacteria sample (500 μ l in TE buffer) and 500 μ l Chloroform were put in a 2 ml microcentrifuge tube for and oscillated by a minibeatbeater, at 4,800 rpm for 2 min. The aqueous phase was collected immediately upon centrifugation. DNA was isolated by 80% ethanol precipitation, dissolved in 50- μ l sterile distilled water and stored in -20°C until assay. DNA samples were amplified for the RD1 region (150 bp) by PCR analysis using the same primers described previously (Parsons et al. 2002). DNA from the H37RV strain of *M. tuberculosis* was used as a positive control. PCR was performed with 5 μ l DNA samples in a total volume of 50 μ l of PCR mix, 5 μ l $10 \times$ buffer, 4 μ l of 2.5 mM dNTP, 1 μ l of Taq DNA polymerase and 0.2 μ l of each primer (50 pmol/ μ l). The mixture was denatured at 95°C for 5 min and cycled for 45 times at 94°C for 30 s than 62°C for 45 s and 68°C for 45 s followed by a final 10-min extension at 68°C . The PCR product was visualized by UV transillumination of ethidine bromide staining after separation by 2% gel electrophoresis.

IGRA ELISPOT assay

The assay was performed as described previously (Guio et al. 2010). Freshly isolated peripheral blood mononuclear cells (2.5×10^5 per well) were cultured on plates precoated with antibody against IFN- γ (IGRA ELISPOT. Oxford Immunotech, Oxford UK). After 18-20 hours stimulation of the cells with Early Secreted Antigenic Target-6 (ESAT-6) and CFP-10, the spots were developed according to the manufacturer's instructions. Spot-forming units (SFUs) were counted with an automated ELISPOT reader (KS ELISPOT Carl Zeiss MicroImaging-Germany). The responses were scored as positive if the test wells contained a mean of at least 5 SFUs more than the mean of the negative control wells and was at least twice the mean of the negative control wells.

Inflammatory markers

Anti-TBGL antibody which recognizes glycolipid (mainly trehalose 6,6'-dimycolate) of MTB and NTMs was measured as described

(Mizusawa et al. 2008). The plasma OPN concentrations were determined using Human OPN Elisa kit (Immuno-Biological Laboratories, Takasaki, Japan) as described (Chagan-Yasutan et al. 2009), and the plasma PTX-3 levels were measured in special reference laboratory (SRL, Hachioji, Japan) (Peri et al. 2000). Plasma levels of leptin were measured as described (Siddiqi et al. 2012).

Statistical analysis

Data were analyzed by statcel2 software (OMS, Tokyo, Japan). Continuous data were compared between groups by Mann Whitney *U* test and significance was considered a *p* value < 0.05 .

Results

Subjects

Profiles of the patients are listed in Table 1. The NTM patients (43 to 83 years old (y.o.)) were infected predominantly by *M. avium complex* (Table 1) and mostly had pulmonary involvement except N6, who had extra-pulmonary involvement (nasal granulomatosis). The duration of illness was variable, ranging from 2 to 148 months. None of them were infected with *M. marinum*, *M. szulgai* or *M. kansasii*, which are known to possess the RD1 region. All the TB patients included in this study (32 to 78 y.o.) had extra-pulmonary disease except T6 (pulmonary TB). All 5 healthy volunteers (25 to 60 y.o.) were apparently healthy without any TB-related symptoms.

Verification of absence of RD1 region and *M. tuberculosis* strains

Absence of the RD1 region in the DNA samples from the clinical strains of the 6 NTM patients (N1-N6) was confirmed by PCR analysis. No positive band was observed at the 150 bp position for the RD1 region in any of the clinical isolates (Fig. 1).




Fig. 1. PCR amplification of RD1 region using DNA obtained from mycobacteria isolated from NTM patients. Arrows indicate the positive bands at 150 bp. N1 to N6, (DNA from 6 NTM patients); H, DNA from *Mycobacterium tuberculosis* (H37RV); M, Marker; R, reagent only.

IGRA and association with the clinical condition

All healthy controls except one were negative for IGRA. Four of 8 NTM patients and all TB patients were positive by IGRA (Table 1). Repeated examination by culture and PCR showed negative for MTB infection in all NTM patients. We further stratified these NTM patients into two subgroups, IGRA-positive as NTM with LTBI (NTM+) and IGRA-negative as NTM without LTBI (NTM-).

Patients in the NTM+ group had pulmonary pathology related to NTM disease based on clinical and radiographic features: consolidation and pulmonary infiltration in N2, both cavity and nodule in N5 and N9 had a combination of bronchiectasis, cavity, consolidation and nodules. Patients of the NTM- group also had typical radiographic features related to NTM infection. The patients of the NTM+ group had symptoms for longer periods (36 to 84 months), whereas the NTM patients had symptoms for variable durations (2 to 148 months), although the difference was not significant. No differences in age or clinical presentation were observed between the NTM+ and NTM- groups. Only patient N5 from the NTM+ group had a history of prior TB infection at the age of 18 that was cured by anti-TB therapy. Among all the NTM patients, only 2 NTM+ patients (N5, N9) had been receiving treatment for NTM infection because of clinical and radiological severities. Patient N5 was treated with rifampicine (RFP), clarithromycin (CAM), ciprofloxacin (CPFX) and ethambutol (EB) for 6 months starting from July 2001. From May 2004, he

was treated again with RFP and CAM, and treatment was continued until October 2005. Since then, he has been treated with different quinolone derivatives including gatifloxacin, CPFX, levofloxacin until June 2006. Finally, the patient was on combined therapy of RFP, CAM and a quinolone derivative until the time of the assay. Patient N9 was also treated with RFP, EB and CAM for 2 months before enrolling in the study. All the other patients hadn't received any drugs for NTM infection. Patients, N5 and N9 had died before the writing of this paper, though detailed information was not available.

Laboratory markers

Laboratory findings are listed in Table 2. There were no significant differences in the conventional markers between the NTM- and + groups. The levels of leptin were apparently lower in the NTM+ and TB groups than in the NTM- group, but no significant differences were found among the groups (Table 2, Fig. 2F).

Inflammatory markers

The data of inflammatory markers are shown (Fig. 2). The TBGL antibody levels are elevated in the NTM+ group and such elevations were unexpectedly not seen in the MTB group, probably because the most of the TB patients were the mild, extra-pulmonary type (Fig. 2A). Patients of the NTM+ group had increased levels of OPN (859 to 1,499 ng/ml) (normal value: < 820 ng/ml; according to Chagan-Yasutan et al. 2009) and the levels were significantly higher

Table 2. Clinical characteristics of patients enrolled in the study.

Laboratory data	Ref. range	Median		
		NTM-	NTM+	TB
RBC ($10^6/\mu\text{l}$)	3.93-5.03	3.915	3.74	3.76
WBC (/ μl)	3.2-9.6	5,250	5,650	4,100
Neutrophil %	31-73	62	58.5	69
Eosinophil %	0-7	1	2	1
Basophil %	0-3	0.5	0.5	0.005
Lymphocyte %	18-51	27	30.5	5
Monocyte %	1-12	8	7.5	5
Platelets ($10^3/\mu\text{l}$)	155-347	232.5	229.5	277
Hb (g/dl)	11.7-14.8	12.9	11.2	11.7
CRP (mg/dl)	0-0.2	1.2	2.45	0.5
Albumin (g/dl)	4.2-5.3	4.1	3.6	3.7
IgG (mg/dl)	748-1,694	1,320	1,542	1,564
IgM (mg/dl)	33-254	86.5	103	115.5
IgA (mg/dl)	91-391	281	336	295
ESR (30 min) (mm)	(-)	8	11	23
ESR (1 hr) (mm)	(-)	22.5	25	53
KL-6 (U/ml)	105-435	310	315.5	347.5
Leptin (pg/ml)	4,700-32,500	8,105	3,437	4,013

NTM-, IGRA negative non-tuberculosis mycobacterium patients; NTM+, IGRA positive non-tuberculosis mycobacterium patients; TB, tuberculosis patients.




Fig. 2. Comparison of plasma inflammatory molecules. NTM-, NTM patients without LTBI ($n = 4$); NTM+, NTM patients with LTBI ($n = 4$); TB, active TB patients ($n = 5$).

than those of the NTM- ($p < 0.05$) (Fig. 2B). The OPN titers in patients N5 and N9 were very high 1,150 ng/ml and 1,499 ng/ml, respectively (Fig. 2B). The CRP levels were not different between the NTM+ and NTM- groups, but the PTX-3 levels (normal value: < 2.3 U/ml) and sIL-2R (normal value: 122-496 U/ml) were elevated in all NTM+ patients and the difference from the NTM- group was significant ($P < 0.05$) (Fig. 2C, D and E).

Discussion

In the current study, 4 of 8 NTM patients (50%) were found to be LTBI, and their average age was 74.5 y.o. In addition, PCR analysis showed that all of our NTM isolates lacked the RD1 region. An age-dependent increase of LTBI has already been described in Japan, where 9.8% for those aged 60-69 were IGRA ELISA positive (Mori et al. 2007). The excellence of IGRA ELISA to differentiate NTM and TB infection in children in non endemic countries was reported (Detjen et al. 2007). In Japan, only 1-8% of IGRA ELISA positive rate in Japanese patients with MAC disease was reported (Kobashi et al. 2006; Kobashi et al. 2009). However 34-49% IGRA ELISA positive cases were

reported in NTM in endemic countries (Ra et al. 2011). The reasons of high rates of IGRA-positive rates in this study could be explained by IGRA ELISPOT assay employed here. It is known that IGRA ELISA tends to show false negative results among thin elderly people, presumably due to decreased immune levels, whereas IGRA ELISPOT assay might have detected LTBI more sensitively in the elderly patients with NTM disease. It was reported that the long-lasting positive IFN- γ response to antigenic challenge continues for 5 to 10 years following anti-TB therapy (Adams et al. 2008).

NTM+ patients had significantly higher titers of inflammatory markers such as OPN, PTX-3 and sIL-2R, though CRP did not show significant differences (Fig. 2). We also observed sustained high levels of OPN after treatment in NTM+ patients. It is possible that anti-NTM therapy was ineffective because two patients died. Alternatively, persistent elevations of OPN after chemotherapy were already reported by us in AIDS patients treated by anti retroviral therapy (Chagan-Yasutan et al. 2009). Additionally our recent study supports the idea of immune-modulator effect of quinolone which enhance the

production of OPN in human lung epithelial cell line A549 *in vitro* (Shiratori et al. 2012). We assume that the quinolone treatment may be one of the factors of persistent OPN elevation. The increased plasma OPN in TB patients contributed to the disease pathology by activating the IL-12 mediated Th1 immunity (Koguchi et al. 2003). It was also found that OPN expression correlates with an effective inflammatory response and contributes to human resistance against MTB (Nau et al. 2000). In cattle, it was proposed that OPN is a key regulator against *M. avium* (Karcher et al. 2008). Immune responses by *M. avium complex* preferentially depend on the phase of infection in human. Early acute infection causes increased IFN- γ secretion, while the chronic phase has been reported to be associated with copious IL-10 production (Azouaou et al. 1997) with an inclination toward Th2 cytokines (Vouret-Craviari et al. 1997) that may provide protection against chronic diseases. We have already reported that the plasma levels of IFN- γ , OPN and leptins did not show any significant changes between LTBI and non-LTBI health care workers (HCW). Though only LTBI HCWs showed the association of TBGL-IgA antibody titer and serum IFN- γ (Siddiqi et al. in press). Our finding may imply that NTM co-infection with LTBI can synergistically induce large amounts of OPN. The synergistic effect could be explained by the natural resistance associated macrophage protein 1 (NRAMP1) because it was reported as host genetic factor for development of both tuberculosis and NTM, however the involvement of NRAMP1 in OPN production was not studied (Li et al. 2011; Sapkota et al. 2012).

It is also interesting that the PTX-3 levels were significantly higher in the NTM+ group while the CRP levels did not differ. It was documented that 5 of 220 TB contacts who developed active TB within 5 to 12 months of follow-up had elevated levels of PTX-3 (Azzuri et al. 2005). The PTX3 haplotype frequencies significantly differed in TB cases compared to controls, and a protective effect against MTB was found in association with a specific haplotype (Olesen et al. 2007). Hence, Th1 mediated PTX-3 production in mycobacterial infection also warrants further investigation.

In conclusion, frequent LTBI was detected in aged NTM patients, and these patients expressed higher levels of inflammatory markers than NTM without LTBI patients. The low number of patients is the main limitation of this study, but careful observation and extensive therapeutic intervention appear to be necessary in NTM with LTBI patients.

Acknowledgments

The authors are grateful for international collaborative study grants from Ministry of Education, Cultural, Sports, Science and Technology, Japan. We also acknowledge central research laboratory, Tohoku University Hospital for providing clinical mycobacterial samples.

Conflict of Interest

The authors declare no conflict of interest.

References

- Adams, L.V., Waddell, R.D. & Von Reyn, C.F. (2008) T-SPOT.TB Test[®] results in adults with *Mycobacterium avium complex* pulmonary disease. *Scand. J. Infect. Dis.*, **40**, 196-203.
- Azouaou, N., Petrofsky, M., Young, L.S. & Bermudez, L.E. (1997) *Mycobacterium avium* infection in mice is associated with time-related expression of Th1 and Th2 CD4+ T-lymphocyte response. *Immunology*, **91**, 414-420.
- Azzuri, A., Sow, O.Y., Amedei, A., Bah, B., Diallo, S., Peri, G., Benagiano, M., D'Elios, M.M., Mantovani, A. & Del Prete, G. (2005) IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in *Mycobacterium tuberculosis* infection. *Microbes Infect.*, **7**, 1-8.
- Chagan-Yasutan, H., Saitoh, H., Ashino, Y., Arikawa, T., Hirashima, M., Li, S., Usuzawa, M., Oguma, S., Telan, E.F., Obi, C.L. & Hattori, T. (2009) Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. *Tohoku J. Exp. Med.*, **218**, 285-292.
- Detjen, A.K., Keil, T., Roll, S., Hauer, B., Mauch, H., Wahn, U. & Magdorf, K. (2007) Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. *Clin. Infect. Dis.*, **45**, 322-328.
- Garlanda, C., Bottazzi, B., Bastone, A. & Mantovani, A. (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. *Annu. Rev. Immunol.*, **23**, 337-366.
- Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., Holland, S.M., Horsburgh, R., Huit, G., Iademarco, M.F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C.F., Wallace, R.J. Jr. & Winthrop, K.: ATS Mycobacterial Diseases Subcommittee. (2007) An Official ATS/IDSA Statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am. J. Respir. Crit. Care Med.*, **15**, 175, 367-416.
- Guio, H., Ashino, Y., Saitoh, H., Siddiqi, U.R., Mizusawa, M., Xiao, P., Soto, A., Theo, A. & Hattori, T. (2010) High numbers of interferon-gamma-producing T cells and low titers of anti-tuberculous glycolipid antibody in individuals with latent tuberculosis. *Tohoku J. Exp. Med.*, **220**, 21-25.
- Infanzato, A., Bottazzi, B., Garlanda, C., Valentino, S. & Mantovani, A. (2012) Pentraxins in humoral innate immunity. *Adv. Exp. Med. Biol.*, **946**, 1-20.
- Ito, Y., Hirai, T., Maekawa, K., Fujita, K., Imai, S., Tatsumi, S., Handa, T., Matsumoto, H., Muro, S., Niimi, A. & Mishima, M. (2012) Predictors of 5-year mortality in pulmonary *Mycobacterium avium-intracellulare complex* disease. *Int. J. Tuberc. Lung Dis.*, [Jan. 5. Epub ahead of print.]
- Karcher, E.L., Bayles, D.O., Bannantine, J.P., Beitz, D.C. & Stabel, J.R. (2008) Osteopontin: a novel cytokine involved in the regulation of *Mycobacterium avium* subspecies paratuberculosis infection in periparturient dairy cattle. *J. Dairy Sci.*, **91**, 3079-3091.
- Khan, Z., Miller, A., Bachan, M. & Donath, J. (2010) *Mycobacterium avium* Complex (MAC) Lung Disease in Two Inner City Community Hospitals: recognition, prevalence, co-infection with *Mycobacterium tuberculosis* (MTB) and Pulmonary Function (PF) Improvements After Treatment. *The Open Respir. Med. J.*, **4**, 76-81.
- Kikuchi, T., Watanabe, A., Gomi, K., Sakakibara, T., Nishimori, K., Daito, H., Fujimura, S., Tazawa, R., Inoue, A., Ebina, M., Tokue, Y., Kaku, M. & Nukiwa, T. (2009) Association

- between mycobacterial genotypes and disease progression in *Mycobacterium avium* pulmonary infection. *Thorax*, **64**, 901-907.
- Kobashi, Y., Obase, Y., Fukuda, M., Yoshida, K., Miyashita, N. & Oka, M. (2006) Clinical Reevaluation of the QuantiFERON TB-2G Test as a Diagnostic Method for Differentiating Active Tuberculosis from Nontuberculous Mycobacteriosis. *Clin. Infect. Dis.*, **43**, 1540-1546.
- Kobashi, Y., Mouri, K., Yagi, S., Obase, Y., Miyashita, N., Okimoto, N., Matsushima, T., Kageoka, T. & Oka, M. (2009) Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease. *Int. J. Tuberc. Lung Dis.*, **13**, 1422-1426.
- Koguchi, Y., Kawakami, K., Uezu, K., Fukushima, K., Kon, S., Maeda, M., Nakamoto, A., Owan, I., Kuba, M., Kudeken, N., Azuma, M., Yara, S., Shinzato, T., Higa, F., Tateyama, M., Kadota, J., Mukae, H., Kohno, S., Uede, T. & Saito, A. (2003) High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. *Am. J. Respir. Crit. Care Med.*, **15**, 167, 1355-1359.
- Li, X., Yang, Y., Zhou, F., Zhang, Y., Lu, H., Jin, Q. & Gao, L. (2011) SLC11A1 (NRAMP1) polymorphisms and tuberculosis susceptibility: updated systematic review and meta-analysis. *PLoS One*, **6**, 1, e15831.
- Mizusawa, M., Kawamura, M., Takamori, M., Kashiyama, T., Fujita, A., Usuzawa, M., Saitoh, H., Ashino, Y., Yano, I. & Hattori, T. (2008) Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis. *Clin. Vaccine Immunol.*, **15**, 544-548.
- Mori, T., Harada, N., Higuchi, K., Sekiya, Y., Uchimura, K. & Shimao, T. (2007) Waning of the specific interferon-gamma response after years of tuberculosis infection. *Int. J. Tuberc. Lung Dis.*, **11**, 9, 1021-1025.
- Nakajima, C., Rahim, Z., Fukushima, Y., Sugawara, I., van der Zanden, A.G., Tamaru, A. & Suzuki, Y. (2010) Identification of *Mycobacterium tuberculosis* clinical isolates in Bangladesh by a species distinguishable multiplex PCR. *BMC Infect. Dis.*, **15**, 118.
- Nau, G.J., Chupp, G.L., Emile, J.F., Jouanguy, E., Berman, J.S., Casanova, J.L. & Young, R.A. (2000) Osteopontin Expression Correlates with Clinical Outcome in Patients with Mycobacterial Infection. *Am. J. Pathol.*, **157**, 37-42.
- Olesen, R., Wejse, C., Velez, D.R., Bisseeye, C., Sodemann, M., Aaby, P., Rabna, P., Worwui, A., Chapman, H., Diatta, M., Adegbola, R.A., Hill, P.C., Østergaard, L., Williams, S.M. & Sirugo, G. (2007) DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. *Genes Immunol.*, **8**, 456-467.
- Parsons, L.M., Brosch, R., Cole, S.T., Somoskövi, A., Loder, A., Bretzel, G., Van Soolingen, D., Hale, Y.M. & Salfinger, M. (2002) Rapid and simple approach for identification of *Mycobacterium tuberculosis* complex isolates by PCR-based genomic deletion analysis. *J. Clin. Microbiol.*, **40**, 2339-2345.
- Peri, G., Introna, M., Corradi, D., Iacuiti, G., Signorini, S., Avanzini, F., Pizzetti, F., Maggioni, A.P., Moccetti, T., Metra, M., Cas, L.D., Ghezzi, P., Sipe, J.D., Re, G., Olivetti, G., Mantovani, A. & Latini, R. (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. *Circulation*, **102**, 636-641.
- Prince, D.S., Peterson, D.D., Steiner, R.M., Gottlieb, J.E., Scott, R., Israel, H.L., Figueroa, W.G. & Fish, J.E. (1989) Infection with *Mycobacterium avium* complex in patients without predisposing conditions. *N. Engl. J. Med.*, **321**, 863-868.
- Ra, S.W., Lyu, J., Choi, C.M., Oh, Y.M., Lee, S.D., Kim, D.S. & Shim, T.S. (2011) Distinguishing tuberculosis from *Mycobacterium avium* complex disease using an interferon-gamma release assay. *Int. J. Tuberc. Lung Dis.*, **15**, 635-640.
- Sapkota, B.R., Hijikata, M., Matsushita, I., Tanaka, G., Ieki, R., Kobayashi, N., Toyota, E., Nagai, H., Kurashima, A., Tokunaga, K. & Keicho, N. (2012) Association of SLC11A1 (NRAMP1) polymorphisms with pulmonary *Mycobacterium avium* complex infection. *Hum. Immunol.*, [Feb. 16. Epub ahead of print]
- Shiratori, B., Zhang, J., Usami, O., Chagan-Yasutan, H., Suzuki, Y., Nakajima, C., Uede, T. & Hattori, T. (2012) Quinolone-induced up-regulation of osteopontin gene promoter activity in human epithelial cell line A549. *Antimicrob. Agents Chemother.*, [Mar. 19. Epub ahead of print]
- Siddiqi, U.R., Leano, P.S.A., Chagan-Yasutan, H., Shiratori, B., Saitoh, H., Ashino, Y., Suzuki, Y., Hattori, T. & Telan, E. (2012) Frequent detection of anti-tubercular-glycolipid IgG and IgA antibodies in the healthcare workers with latent tuberculosis infection in the Philippines. *Clin. Immunol. Dev.* (in press)
- Siddiqi, U.R., Pupunich, W., Chuchottaworn, C., Jindakul, S., Ashino, Y., Saitoh, H., Okada, M., Chotpitayasonondh, T. & Hattori, T. (2012) Evaluated anti-tuberculous glycolipid antibody titers in healthy adults and tuberculosis patients in Thailand. *Int. J. Tuberc. Lung Dis.*, [Feb. 8. Epub ahead of print.]
- Takeda, M., Ito, W., Kobayashi, N., Konno, K., Takahashi, T., Tatsuko, R., Tomita, N., Tanigai, T., Chiba, T., Yamaguchi, K., Sato, K., Ueki, S., Kayaba, H. & Chihara, J. (2008) Co-existence of *Mycobacterium tuberculosis* and *Mycobacterium intracellulare* in one sputum sample: case report. *Inter. Med.*, **47**, 1057-1060.
- van Leeuwen, L., Bossink, A.W.J. & Thijsen, S.F.T. (2007) Exclusion of active *Mycobacterium tuberculosis* complex infection with the T-SPOT.TB assay. *Eur. Respir. J.*, **29**, 605-607.
- Vouret-Craviari, V., Matteucci, C., Peri, G., Poli, G., Introna, M. & Mantovani, A. (1997) Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. *Infect. Immun.*, **65**, 1345-1350.
- Wang, J.Y., Chou, C.H., Lee, L.N., Hsu, H.L., Jan, I.S., Hsueh, P.R., Yang, P.C. & Luh, K.T. (2007) Diagnosis of Tuberculosis by an Enzyme-Linked Immunospot Assay for Interferon- γ . *Emerg. Infect. Dis.*, **13**, 553-558.

Genotypes and Characteristics of Clustering and Drug Susceptibility of *Mycobacterium tuberculosis* Isolates Collected in Heilongjiang Province, China[∇]

Juan Wang,^{1†} Yan Liu,^{2†} Chun-Lei Zhang,^{3†} Bin-Ying Ji,³ Liu-Zhuo Zhang,² Yong-Zhen Shao,^{1‡} Shui-Lian Jiang,¹ Yasuhiko Suzuki,⁴ Chie Nakajima,⁴ Chang-Long Fan,³ Yuan-Ping Ma,¹ Geng-Wen Tian,¹ Toshio Hattori,⁵ and Hong Ling^{1*}

Department of Microbiology and Parasitology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Key Lab of Heilongjiang Province, Education Bureau for Etiology,¹ and Department of Biostatistics,² Harbin Medical University, Harbin, China; Harbin Chest Hospital, Harbin, China³; Department of Global Epidemiology, Hokkaido University, Research Center for Zoonosis Control, Hokkaido, Japan⁴; and Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University, Japan⁵

Received 11 November 2010/Returned for modification 18 November 2010/Accepted 4 February 2011

For the last decade China has occupied second place, after India, among the top five countries with high burdens of tuberculosis (TB). Heilongjiang Province is located in northeastern China. The prevalence of drug-resistant TB in Heilongjiang Province is higher than the average level in China. To determine the transmission characteristics of *Mycobacterium tuberculosis* strains isolated in this area and their genetic relationships, especially among the Beijing family strains, we investigated their genotypes. From May 2007 to October 2008, 200 *M. tuberculosis* isolates from patients presenting pulmonary TB were analyzed by molecular typing using PCR-based methods: spacer-oligonucleotide typing (spoligotyping), Beijing family-specific PCR (detection of the deletion of region of difference 105 [RD105]), and mycobacterial interspersed repetitive-unit-variable-number tandem-repeat (MIRU-VNTR) analysis. Different combinations of MIRU-VNTR loci were evaluated to define the genotypes and clustering characteristics of the local strains. We found that Beijing family strains represented 89.5% of the isolates studied. However, the rates of multidrug-resistant (MDR) *M. tuberculosis* among Beijing and non-Beijing family strains were not statistically different. The 15-locus set is considered the optimal MIRU-VNTR locus combination for analyzing the *M. tuberculosis* strains epidemic in this area, while the 10-locus set is an ideal set for first-line molecular typing. We found that the clustering rate of all the *M. tuberculosis* isolates analyzed was 10.0% using the 15-locus set typing. We conclude that the Beijing family genotype is predominant and that highly epidemic TB and MDR TB are less likely associated with the active transmission of *M. tuberculosis* in the study area.

Tuberculosis (TB) remains a major public health threat worldwide. China has occupied second place, after India, among the top five high-burden countries for the last decade (<http://www.who.int/tb/en>). Although both the incidence and prevalence of TB in China have shown a steady decline in recent years, it remains a leading notifiable infectious disease (<http://www.moh.gov.cn>). Currently, the spread of drug-resistant TB, especially multidrug-resistant (MDR) TB, in China, presents a major challenge. The most up-to-date data from the World Health Organization (WHO) indicates that the rate of MDR TB in China was 8.3% (the rates of primary and acquired MDR TB were 5.7% and 25.6%, respectively) in 2007 (50), significantly higher than the global average rate (3.6%). The higher levels of TB prevalence and drug resistance have become the main public health concern of the Chinese government.

Heilongjiang Province, located in northeastern China, is one of the regions where the prevalence of both TB and drug-resistant TB is higher than the average level in China. The most recently updated epidemiological data, from 2007 to 2008, show that the rates of primary and acquired MDR TB were 18.3% and 37.8%, respectively, in Heilongjiang Province (our unpublished data). The reasons for the high prevalence and drug resistance of TB in Heilongjiang Province are still unknown and should be investigated to facilitate control of the TB epidemic in this area and throughout China.

In several Asian countries with high TB rates, a unique genotype of *Mycobacterium tuberculosis*, known as the Beijing family genotype, has been found to be the dominant genotype (3, 17, 34). During the last decade, Beijing family strains have been spreading in various geographic locations worldwide and now account for more than a quarter of all TB cases worldwide (12). Possible associations of the epidemic caused by this genotype with its drug resistance (1, 41) and its high adaptability to the host intracellular environment (8) have been reported. In China, Beijing family strains have spread widely; however, the proportion of Beijing family strains in Heilongjiang Province remains unknown. It is thus unclear if the high prevalence and high drug resistance of epidemic TB are directly related to the spread of Beijing family strains. The answers to these

* Corresponding author. Mailing address: Department of Microbiology, Harbin Medical University, 194 Xuefu Road, Harbin 150081, Heilongjiang Province, China. Phone and fax: 86 451 86685122. E-mail: yfirling@yahoo.com.

† J.W., Y.L., and C.-L.Z. contributed equally to this work.

‡ Present address: Dalian University Affiliated Xinhua Hospital, Dalian, China.

[∇] Published ahead of print on 16 February 2011.